Main Industry
Biotechnology
Main Product/Service
Pharmaceutical R&D
1. Acute Kidney Injury
2. Acute Ischemic Stroke
3. Chemosensitizers
1. Acute Kidney Injury
2. Acute Ischemic Stroke
3. Chemosensitizers
The content above was translated by Ai
Founded Year
2014
Unified Business No.
24618497
Status
Active
Number of Employees
0
Total Paid-in
Capital
81,460,000 (NT$)
Location of Company
Taiwan
, Taoyuan City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
REALINN LIFE SCIENCE LIMITED was established in July 2014, with Chairman Lin Chong-jen serving as the company's representative. The capital is NT$54.2 million (as of 2024). The head office is located in Dayuan District, Taoyuan City, and the Zhonghe office is located in the Biomedical Park Incubation Center of Shuang Ho Hospital in Zhonghe District, New Taipei City.
The team of REALINN LIFE SCIENCE LIMITED possesses outstanding professional talents and rich practical clinical experience. Collaborating with the National Defense Medical Center, Taipei Medical University, Kaohsiung Medical University, the Development Center for Biotechnology, and a multi-disciplinary group of expert consultants, the company focuses on drug research and development. Adopting a research project model, it focuses on new drug development and is committed to reducing the risk coefficient of new drug development. Its diligent, down-to-earth, and step-by-step R&D strength is demonstrated in three drug R&D fields, and it has obtained multiple invention patent certificates to date. REALINN LIFE SCIENCE LIMITED holds multiple drug patent rights in Taiwan, and has also individually obtained patent certifications in several major countries and regions, including registration with the U.S. Food and Drug Administration (FDA), Japan, the European Union (prior to Brexit), and Australia.
In 2025, REAL208 (a new drug for septic acute kidney injury) has progressed to the toxicity testing stage and the second scale-up process. REAL208 is planned to obtain IND (Investigational New Drug) approval and initiate Phase I clinical trials in the United States in 2026.
The team of REALINN LIFE SCIENCE LIMITED possesses outstanding professional talents and rich practical clinical experience. Collaborating with the National Defense Medical Center, Taipei Medical University, Kaohsiung Medical University, the Development Center for Biotechnology, and a multi-disciplinary group of expert consultants, the company focuses on drug research and development. Adopting a research project model, it focuses on new drug development and is committed to reducing the risk coefficient of new drug development. Its diligent, down-to-earth, and step-by-step R&D strength is demonstrated in three drug R&D fields, and it has obtained multiple invention patent certificates to date. REALINN LIFE SCIENCE LIMITED holds multiple drug patent rights in Taiwan, and has also individually obtained patent certifications in several major countries and regions, including registration with the U.S. Food and Drug Administration (FDA), Japan, the European Union (prior to Brexit), and Australia.
In 2025, REAL208 (a new drug for septic acute kidney injury) has progressed to the toxicity testing stage and the second scale-up process. REAL208 is planned to obtain IND (Investigational New Drug) approval and initiate Phase I clinical trials in the United States in 2026.
The content above was translated by Ai
